The purpose of the trial is to determine whether the experimental drug can lower disease activity compared with a placebo. Adults will be randomly assigned to receive either the study drug or the placebo, and neither the participants nor the study staff will know which treatment is given. Injections will be given at regular intervals over about six months, with clinic visits to assess muscle strength, skin involvement, and any side effects. Researchers will track changes using simple scores that measure overall improvement and skin disease activity, and they will also monitor whether participants can reduce their steroid dose safely.

The purpose of this study is to assess the safety of cizutamig in patients with these severe inflammatory conditions and to examine how well the treatment works in controlling disease activity. During the study, patients will receive the medication and will be closely monitored for any side effects, particularly Cytokine Release Syndrome and other treatment-related reactions. The study will track various measures of disease activity specific to each condition, such as skin thickness scores for systemic sclerosis, muscle strength measurements for inflammatory myopathy, disease activity scores for rheumatoid arthritis, and symptom scores for Sjögren’s disease. For patients who have lung involvement, lung function tests will also be performed.

The study will last approximately 52 weeks, with regular assessments at different time points to evaluate both the safety and effectiveness of the treatment. Patients will have measurements taken at weeks 16, 24, and 52 to see how their disease responds to cizutamig. The study will also look at whether patients can reduce or stop other medications they may be taking, how often their disease flares up, and how their overall quality of life and daily functioning change during the treatment period.

The purpose of this study is to evaluate the safety of this cell therapy in patients whose autoimmune disease has continued to progress despite receiving treatments that remove B cells from the body. B cells are a type of immune cell that produces antibodies, and in autoimmune diseases, these cells can contribute to the harmful immune response. The study will specifically look at serious side effects including problems with the immune system’s response to the treatment, such as cytokine release syndrome and nervous system complications, as well as damage to organs that does not improve quickly.

During the study, patients will receive the modified T cell treatment and will be closely monitored for any side effects and how their body responds to the therapy. The study will track whether patients experience any severe reactions and how long it takes for these reactions to resolve with appropriate medical care. Patients participating in this study will have already tried multiple standard treatments for their autoimmune disease without success, including at least one treatment specifically designed to eliminate B cells from the body.

The purpose of the study is to evaluate the use of 68Ga-FAPI-46 to detect scar tissue inside the body. This substance is a radiopharmaceutical, which is a specialized drug used for medical imaging. Participants will undergo a PET/CT scan, a method that combines two types of imaging to create detailed pictures of the body’s internal structures. During the process, the substance is administered through an intravenous injection, meaning it is delivered directly into a vein.

Throughout the study, the imaging results will be compared with biological samples to see how well the scan identifies certain markers of scarring. Researchers will also look at how the substance moves through the body and how it can be used to better understand the progression of these diseases. This information may help in finding new ways to diagnose or treat scarring in the future.

The purpose of the study is to assess the safety of CNTY-101 in people with active autoimmune diseases driven by B-cells, which are a type of immune cell. Participants in the study will receive the treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants over time to see how they respond to the treatment and to check for any side effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the potential benefits and risks of using CNTY-101 for treating these autoimmune diseases. This research could lead to new ways of managing these conditions in the future.

Participants in this study will receive dazukibart, which is a type of medication known as a monoclonal antibody. This medication is designed to target and neutralize specific proteins in the body that may contribute to inflammation. The study will also involve other medications, including betamethasone, hydroxychloroquine, chloroquine phosphate, hydrocortisone, triamcinolone acetonide, methylprednisolone, mycophenolate mofetil, budesonide, dexamethasone, azathioprine, prednisolone, methotrexate, deflazacort, leflunomide, and prednisone. Some participants may receive a placebo instead of the active medication.

The study will last for up to 52 weeks, during which participants will be monitored for any side effects and changes in their condition. The goal is to gather information on the safety of dazukibart and its effectiveness in managing symptoms of idiopathic inflammatory myopathies. Participants will undergo regular check-ups and assessments to track their progress and any changes in their health status.

The purpose of the study is to evaluate how well efgartigimod PH20 SC works in improving the symptoms of IIM, as well as to assess its safety and how well it is tolerated by participants. Participants in the study will receive either the investigational treatment or a placebo, and their progress will be monitored over a period of time to see if there are any improvements in their condition. The study will also look at how the body processes the treatment and whether it causes any immune reactions.

Throughout the study, participants will undergo various assessments to measure changes in muscle strength and overall disease activity. These assessments will help determine the effectiveness of the treatment in providing clinical improvement for those with active IIM. The study aims to provide valuable information on whether efgartigimod PH20 SC can be a beneficial treatment option for individuals with this condition.

The purpose of the study is to assess the safety of this new treatment in patients with active forms of these autoimmune diseases. Participants in the study will receive the treatment through an infusion, which means it will be administered directly into the bloodstream. The study will monitor participants for any side effects or reactions to the treatment, particularly focusing on any signs of Cytokine Release Syndrome and CAR T cell Associated Neurotoxicity Syndrome within the first few weeks after receiving the treatment.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the potential of this innovative therapy for managing these challenging autoimmune diseases. The trial is expected to continue until 2026, allowing researchers to collect comprehensive data on the treatment’s safety and effects over time.

The purpose of this research is to determine if adding early intravenous immunoglobulin treatment to standard prednisone therapy helps patients with newly diagnosed myositis achieve better results after 12 weeks. The medication being tested is Nanogam, which is given through an intravenous (into the vein) infusion, along with sodium chloride solution.

During the study, participants receive either the combination of immunoglobulin and prednisone or prednisone with placebo. The treatment period lasts for three months, during which patients receive multiple infusions. The study is “double blind,” which means neither the patients nor their doctors know which treatment combination each participant receives until the study is complete.